v3.26.1
INCOME TAX (Tables)
12 Months Ended
Dec. 31, 2025
Income Tax Disclosure [Abstract]  
Schedule of loss before income taxes
   
Year ended December 31
 
   
2025
   
2024
 
Entera Bio Ltd.(domestic)
   
11,436
     
9,479
 
Entera Bio Inc.(foreign)
   
3
     
48
 
Total loss before taxes
   
11,439
     
9,527
 
Schedule of tax expenses
   
Year ended December 31
 
Current:
 
2025
   
2024
 
Subsidiary: (foreign)
   
-
     
-
 
Total current income tax
   
-
     
-
 
Deferred income taxes – subsidiary (foreign)
   
-
     
14
 
Total deferred income taxes
   
-
     
14
 
Total income tax expense
   
-
     
14
 
Schedule of deferred income taxes
   
December 31,
 
Deferred tax assets:
 
2025
   
2024
 
Net operating loss carry forward
   
21,114
     
19,208
 
Research and development
   
1,027
     
854
 
Share-based compensation
   
687
     
639
 
Other
   
133
     
172
 
Net deferred tax assets before valuation allowance
   
22,961
     
20,873
 
Valuation allowance
   
(22,961
)
   
(20,873
)
Net deferred tax assets
   
-
     
-
 
Schedule of rollforward of valuation allowance
Balance at January 1, 2024
   
19,471
 
Additions
   
1,402
 
Balance at January 1, 2025
   
20,873
 
Additions
   
2,088
 
Balance at December 31, 2025
   
22,961
 
Schedule of rconciliation of statutory tax rate
   
Year Ended December 31, 2025
   
Year Ended December 31, 2024
 
    $    
%
    $    
%
 
Statutory corporate tax rate
   
(2,630
)
   
(23
)
   
(2,202
)
   
(23
)
Foreign tax effects
                               
United States
   
(1
)
   
*
     
(3
)
   
*
 
Non-taxable or non-deductible items:
                               
Share-based compensation
   
535
     
(23
)
   
815
     
(23
)
Other
   
8
     
(23
)
   
2
     
(23
)
                                 
Change in valuation allowance
   
2,088
     
(23
)
   
1,402
     
(23
)
Effective tax rate
   
-
     
-
     
14
     
*